However, the efficacy of ICIs in patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR)-sensitive mutations (exon 19 deletion/exon 21 L858R mutation) is disappointing and usually results in severe adverse events3–6. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.